Development and Validation of the Houston-BEST, a Barrett’s Esophagus Risk Prediction Model Adaptable to Electronic Health Records

Abstract

Esophageal adenocarcinoma (EAC) incidence is projected to rise in the United States until at least 2030. 1 Arnold M. et al. Am J Gastroenterol. 2017; 112: 1247-1255 Google Scholar Despite advances in treatment options, 5-year survival remains poor at only 20%, and curative treatment is possible in <30% of cases because most are diagnosed with late-stage disease. 2 Haiyu Z. et al. Biomed Res Int. 2019; 20197431850 Google Scholar Screening for and identification of Barrett’s esophagus (BE) is currently the only viable method to prevent EAC through chemoprevention, surveillance, early detection, and/or endoscopic eradication therapy. 3 El-Serag H.B. et al. Gut. 2016; 65: 1252-1260 Google Scholar